// Habits · Longterm · Don’ts

Project Blueprint: habits, longterm, and don’ts

Three buckets keep practical routines, long-range interpretation, and source-aware caution visible on every protocol surface.

repeatable behaviors

Habits

Run the measurement loop: bloodwork, wearables, oral/skin/organ metrics, then retest instead of relying on vibes.
Keep the stable inputs visible first: consistent sleep, training, nutrient-dense meals, oral care, light exposure, and recovery.

durable strategy

Longterm

Treat Blueprint as a repeatable feedback system whose rules can evolve as biomarkers, symptoms, or evidence change.
Track the June 2026 sauna/HSP27 thread as a protocol-design case study: Johnson shifted the dose question from minutes in the sauna to measured core temperature and biomarker response.
Track the June 2026 jet-lag follow-up as a self-reported caffeine + melatonin test using blood glucose as a body-clock readout, not as general travel medical advice.
Treat the June 2026 Australian sun/skin-aging post as a skin-readout example inside the measurement loop, not as validated skincare advice.
Treat the June 2026 Immortals Rx expansion separately from foundational habits; the GLP-1, SGLT2, peptide, and NAD+ catalog is a commercial/protocol claim that requires clinician oversight.
Treat Johnson’s June 2026 “one international trip per quarter” rule as a biomarker-derived personal boundary, not as a reader travel guideline.
Treat the June 2026 inherited-cancer DNA + RNA panel as germline risk-stratification context, not a diagnosis, universal screening recommendation, or validation of Johnson’s early-surveillance statistics.
Treat the July 2026 AIG single-cell immune-receptor sequencing thread as Johnson’s diagnostic follow-through: a cellular/receptor-level measurement layer, not a validated therapy or reader test recommendation.
Preserve medical-caution framing: this page summarizes Johnson/Blueprint practice, not personal treatment advice.

guardrails

Don’ts

Do not present N=1 biomarker movement as proof of clinical outcomes.
Do not mix experimental drugs, hormones, or supplements into the same confidence tier as sleep, exercise, and food quality.

Project Blueprint

Project Blueprint is bryan johnson’s longevity protocol and commercial health platform. It began as an N=1 self-experiment: measure organ systems and biomarkers, choose interventions from literature and clinical practice, implement them with a medical team, then re-measure. Johnson’s 2021 framing was explicitly system-oriented: his body would generate the “grocery shopping list,” and the core innovation was a feedback loop where organs and biomarkers outranked momentary preference.

By 2026, Blueprint had expanded into a public “Protocol Marketplace,” supplements/foods/skincare, certified products, biomarker testing, an AI health companion, and user-facing protocol personalization. The biomarker page advertises urine and blood testing, 100+ biomarkers, 160+ measurements per year, past-lab import, six-month retesting, and AI-generated evidence-backed protocol guidance.

Methodology

The methodology is a closed-loop optimization system:

Define a health/longevity target, often in terms of biological age, organ age, or speed of aging.
Measure extensively: blood/urine biomarkers, imaging, functional tests, wearable data, and epigenetic clocks.
Choose interventions using scientific literature, clinical practice, and self-experimentation.
Run the protocol with discipline: diet, sleep, exercise, supplements, prescriptions, devices, imaging, and occasional experimental therapies.
Re-measure, drop failures, iterate.

This makes Blueprint a concrete example of biomarker driven longevity protocols: the decision system is the product, not just any one food, supplement, or device.

Claimed benefits and accessible core

Johnson’s protocol materials emphasize simple, repeatable behaviors as well as expensive testing: lower resting heart rate before bed, keep a consistent bedtime, stop food several hours before sleep, avoid evening screens, exercise, and measure progress. His X/Twitter posts in May 2026 repeatedly returned to sleep timing, RHR, sauna, vaccines, peptides, and the idea that “biomarkers in context” are more useful than raw measurement.

Commercialization

Blueprint has become a product ecosystem. Its site offers protocols and products by benefit area (daily health/longevity, brain/heart, energy/stress, muscle/recovery, nutrition, gut/immune, hair/skin), and claims its products are built on population-level studies, tested, and certified. Biomarkers membership is positioned as a lower-cost way to bring Johnson’s “scientific framework” to users.

Limits and critiques

The core scientific limitation is N=1: Johnson changed many variables simultaneously, with no control group, making causal attribution impossible. YEARS emphasizes that data volume and clinical relevance are different; epigenetic clocks are predictors, not proof that a lower score adds healthy years. MDLinx similarly notes that some elements (sleep, exercise, some monitoring) have support, while other aspects — 100+ supplements, extensive imaging, off-label/experimental interventions — may not be generalizable or necessary.

The practical takeaway is to separate Blueprint into layers: evidence-backed basics (sleep, exercise, nutrition, clinically indicated testing), data-driven personalization, commercial products, and experimental/medical interventions. The first two are broadly useful concepts; the latter two require stronger skepticism, medical supervision, and conflict-of-interest awareness.

bryan johnson — person and source of the protocol.
dont die — ideological/community wrapper around Blueprint.
biomarker driven longevity protocols — abstracted concept and evaluation frame.